Dan Werb




Dan Werb, PhD, is an epidemiologist and policy analyst with expertise in overdose, Human Immunodeficiency Virus (HIV), addictions, and drug policy. Dr. Werb is a Research Scientist at the Li Ka Shing Knowledge Institute (LKSKI) at St. Michael’s Hospital in Toronto. He is also an Assistant Professor in the Division of Infectious Diseases & Global Public Health at the University of California, San Diego. Dr.Werb is Director of the Centre on Drug Policy Evaluation, a recognized global leader in cutting edge policy research and communications. Dr. Werb has published dozens of studies on issues related to health policy and addictions, with a focus on preventing the transition of street youth into injection drug use, as well as on identifying the impact of policy and public health interventions on street-based drug-using populations.

Please note: Dr. Werb is not taking any summer students.


Recent Publications

  1. Meyers, SA, Earnshaw, VA, D'Ambrosio, B, Courchesne, N, Werb, D, Smith, LR et al.. The intersection of gender and drug use-related stigma: A mixed methods systematic review and synthesis of the literature. Drug Alcohol Depend. 2021;223 :108706. doi: 10.1016/j.drugalcdep.2021.108706. PubMed PMID:33901753 .
  2. Ti, L, Tobias, S, Maghsoudi, N, Milloy, MJ, McDonald, K, Shapiro, A et al.. Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings. Drug Alcohol Rev. 2021;40 (4):580-585. doi: 10.1111/dar.13237. PubMed PMID:33354869 .
  3. Sa, M, C, R, Ml, M, Lr, S, J, TM, S, J et al.. Examining the gender composition of drug injecting initiation events: A mixed methods investigation of three North American contexts. Int J Drug Policy. 2021;90 :103056. doi: 10.1016/j.drugpo.2020.103056. PubMed PMID:33310638 PubMed Central PMC8046711.
  4. Scheim, AI, Bouck, Z, Tookey, P, Hopkins, S, Sniderman, R, McLean, E et al.. Supervised consumption service use and recent non-fatal overdose among people who inject drugs in Toronto, Canada. Int J Drug Policy. 2021;87 :102993. doi: 10.1016/j.drugpo.2020.102993. PubMed PMID:33160158 .
  5. Bernstein, SE, Amirkhani, E, Werb, D, MacPherson, D. The regulation project: Tools for engaging the public in the legal regulation of drugs. Int J Drug Policy. 2020;86 :102949. doi: 10.1016/j.drugpo.2020.102949. PubMed PMID:33049592 PubMed Central PMC7547323.
  6. Meyers, SA, Rafful, C, Jain, S, Sun, X, Skaathun, B, Guise, A et al.. The role of drug treatment and recovery services: an opportunity to address injection initiation assistance in Tijuana, Mexico. Subst Abuse Treat Prev Policy. 2020;15 (1):78. doi: 10.1186/s13011-020-00322-1. PubMed PMID:33046125 PubMed Central PMC7552370.
  7. Gicquelais, RE, Werb, D, Marks, C, Ziegler, C, Mehta, SH, Genberg, BL et al.. Prevalence and Correlates of Providing and Receiving Assistance With the Transition to Injection Drug Use. Epidemiol Rev. 2020;42 (1):4-18. doi: 10.1093/epirev/mxaa008. PubMed PMID:33024995 PubMed Central PMC7947591.
  8. Scheim, AI, Maghsoudi, N, Marshall, Z, Churchill, S, Ziegler, C, Werb, D et al.. Impact evaluations of drug decriminalisation and legal regulation on drug use, health and social harms: a systematic review. BMJ Open. 2020;10 (9):e035148. doi: 10.1136/bmjopen-2019-035148. PubMed PMID:32958480 PubMed Central PMC7507857.
  9. Bloom, BE, Jain, S, Sun, X, Garfein, RS, Strathdee, SA, Milloy, MJ et al.. Self-perception of assisting with future injection drug initiation: The influence of relationships in the process of drug injecting initiation. Drug Alcohol Rev. 2021;40 (1):109-117. doi: 10.1111/dar.13145. PubMed PMID:32840027 PubMed Central PMC7977721.
  10. Meyers, SA, Smith, LR, Werb, D. Preventing transitions into injection drug use: A call for gender-responsive upstream prevention. Int J Drug Policy. 2020;83 :102836. doi: 10.1016/j.drugpo.2020.102836. PubMed PMID:32679459 PubMed Central PMC7793169.
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Division of Global Public Health, University of California San Diego Director, International Centre for Science in Drug Policy